Attention Shareholders: Legal Investigation Launched on Behalf of Investors of …

On November 19, 2024, it was revealed by Arvinas in a submission to the U.S. Securities and Exchange Commission that Arvinas and its collaborator, Pfizer, Inc., would be concluding their agreement for the development and commercialization of ARV-110. ARV-110 is a therapy intended for the treatment of metastatic castration-resistant prostate cancer. This decision came about due to a strategic evaluation by both companies regarding the future development plans for the therapy.

The joint decision by Arvinas and Pfizer, Inc. to discontinue the agreement on ARV-110 was reached following careful consideration and analysis of the therapy’s development and commercialization prospects. Both companies determined that it was in their best interests to part ways and pursue other opportunities independently. While this decision may come as a disappointment to some stakeholders, it reflects the dynamic and evolving nature of the pharmaceutical industry, where partnerships are subject to reevaluation based on changing circumstances.

Arvinas expressed gratitude for its partnership with Pfizer, Inc. and acknowledged the collaborative efforts that had been put forth in advancing the development of ARV-110. The decision to end the agreement was described as a mutual and amicable one, with both companies continuing to maintain a positive relationship despite going their separate ways in this particular endeavor.

Moving forward, Arvinas plans to take full ownership of the development and commercialization of ARV-110. The company remains committed to advancing the therapy through clinical trials and regulatory processes with the goal of bringing it to market for patients in need. While this transition may present certain challenges, Arvinas is well-prepared to take on the responsibilities associated with independent development and commercialization of ARV-110.

Despite the end of their collaboration on ARV-110, Arvinas and Pfizer, Inc. expressed optimism about their respective futures in the pharmaceutical industry. Both companies remain dedicated to pursuing innovative therapies and advancing scientific research in the fight against cancer and other serious diseases. The decision to part ways on ARV-110 does not diminish the commitment of either company to improving patient outcomes and making a meaningful impact in the field of oncology.

In conclusion, the decision by Arvinas and Pfizer, Inc. to end their partnership on ARV-110 marks a significant development in the journey of this therapy towards potential approval and commercialization. While the transition to independent development may present challenges, both companies are positioned to navigate these obstacles and continue their pursuit of bringing innovative treatments to patients in need. The evolving landscape of the pharmaceutical industry underscores the importance of adaptability and strategic decision-making in a rapidly changing environment.